Focus on Health Policy
Click here to read the full report.
Profiles & Reports
Industry Profile 2008
In 2007, America’s biopharmaceutical research companies continued to make record investments in R&D, leading the world in the search for new, potentially life-changing medicines. Find out about the unprecedented potential of today’s science as well as the challenges facing pharmaceutical research companies in the 2008 Pharmaceutical Industry Profile.2008 Industry Profile
Pharmaceutical Marketing & Promotion
Activities conducted as part of pharmaceutical marketing and promotion are an important part of informing consumers and healthcare professionals about new treatments. This booklet offers facts that we believe are important to consider as the value of marketing and promotion is debated.Marketing & Promotion
Drug Discovery and Development
For the first time in history, scientists are beginning to understand the inner workings of human disease at the molecular level. Recent advances in genomics, proteomics and computational powerpresent new ways to understand illness. The task of discovering and developing safe and effective drugs is even more promising as our knowledge of disease increases.
RD Brochure 022307.pdf (3.04 MB)Annual Report 2007
PhRMA’s mission is winning advocacy for public policies that encourage the discovery of life-saving and life-enhancing new medicines for patients by pharmaceutical / biotechnology research companies. The pharmaceutical business is unlike any other. Our goal is not entertainment, enjoyment or prosperity. It is the health of patients. PhRMA member companies are devoted to applying biomedical innovation to create new medicines that will enhance or save the lives of patients around the world.
Read more about our mission in this year's annual report.
2008 Annual ReportCorporate Philanthropy in Asia
A dozen nations and as many companies are represented in this, the first report by the Pharmaceutical Research and Manufacturers of America of philanthropic activities of the world’s leading research-based pharmaceutical companies in Asia. The myriad philanthropic activities found in Corporate Philanthropy in Asia include well over 300 separate initiatives of a wide range of sizes, shapes and purposes.Read this report
Value of Medicines: Facts and Figures 2006
Prescription medicines are key to improving both our health and our health care finances. Today’s medicines make it possible to save and improve lives more than at any other time in human history. New medicines help avert surgeries and trips to the ER, prevent disability, and improve quality of life for patients everywhere. The benefits ripple beyond individual patients to society in general. The charts in this book illustrate the diverse and far-reaching benefits of prescription medicines. Value of Medicine: Facts and Figures 2006.pdf (1.00 MB)Decade of Innovation: Advances in the Treatment of Rare Diseases
In the last 10 years, biopharmaceutical companies have made great progress in the fight against rare diseases. Over 160 drugs were approved during the past decade (1995–2005) to treat rare or “orphan” diseases that affect 200,000 or fewer people in the United States. This compares with 108 approvals in the decade before (1984–1994) and fewer than 10 in the 1970s. Each of these medicines offers hope and relief to patients with diseases that often have no other treatment options. PhRMA Rare Diseases 06.pdf (3.25 MB)Discoverers Award 2006: Zetia®
Zetia® is the first breakthrough in cholesterol-lowering therapies since statins were discovered twenty years ago. Specifically, Zetia® is first in a new class of cholesterol absorption inhibitors. Rather than working with the liver to decrease cholesterol production, as statins do, Zetia® works in the digestive track to block its absorption.Learn more about Zetia®.
Discoverers_award_2006.pdf (552.43 KB)Health Care in the Developing World
An unknown fact about the industry is the important role they play in the global effort to fight disease and improve public health in the developing world. In both absolute and relative terms the industry’s global humanitarian programs are substantial, sustained and effective. In a span of three years the industry’s global healthcare spending increased 148 percent, from $564 million to $1.4 billion. Another study puts the industry’s contribution at $2.1 billion. Our contribution to global health represents more than a third of the United States’ total healthcare assistance to the developing world.
Global_Partnerships_2004.pdf (1.61 MB)The Value of Investment in Health Care Executive Summary
Over the past few decades, significant advances in the U.S. health care system have helped people live longer and better lives. In fact, both mortality and disability rates have fallen consistently since the 1970s. This period has also seen substantial increases in health spending. All too often, health care discussions seem to center on the substantial increase in per person spending on health care during this period, rather than the benefits of improved health care that the spending brought. The Value of Investment in Health Care Executive Summary.pdf (4.47 MB)What Goes Into the Cost of Prescription Drugs?
Whenever we talk about what goes into the cost of prescription drugs, one part of the cost equation overshadows all others: The cost of disease. The cost of disease includes the cost of medications, hospitalizations, doctor visits, physical therapies and surgeries. The cost of disease is growing and it is a burden that falls hardest on patients and their families. It saps financial resources while taking a devastating physical and emotional toll. And, every year, the cost of disease is rising. Cost_of_Prescription_Drugs.pdf (1.40 MB)
A Decade of Innovation: Advances in the Pharmaceutical Treatment of Disease
Over the past decade, pharmaceutical companies have pushed the scientific envelope, working at the cellular and molecular levels to dramatically advance the treatment of disease. At the end of 2002, 28 percent more medicines were being investigated by pharmaceutical companies for approval by the Food and Drug Administration (FDA) than was true one decade before. More than 1,000 medicines are now in the development pipeline.